VECTIVBIO HLDG AG's ticker is VECT and the CUSIP is H9060V101. A total of 52 filers reported holding VECTIVBIO HLDG AG in Q2 2023. The put-call ratio across all filers is 0.68 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $46,945,093 | +5.0% | 2,782,756 | -47.1% | 14.24% | +20.0% |
| Q1 2023 | $44,724,170 | -6.0% | 5,255,484 | -4.3% | 11.87% | -6.3% |
| Q4 2022 | $47,595,916 | +92.6% | 5,492,893 | +33.3% | 12.68% | +90.7% |
| Q3 2022 | $24,717,000 | +21.0% | 4,119,572 | +8.9% | 6.65% | -14.8% |
| Q2 2022 | $20,424,000 | +40.6% | 3,782,199 | +22.6% | 7.80% | +26.3% |
| Q1 2022 | $14,527,000 | +10.6% | 3,084,310 | +15.3% | 6.18% | +41.7% |
| Q4 2021 | $13,136,000 | -34.4% | 2,675,408 | +3.2% | 4.36% | -25.4% |
| Q3 2021 | $20,028,000 | -33.6% | 2,592,602 | +0.3% | 5.85% | -16.7% |
| Q2 2021 | $30,152,000 | – | 2,585,986 | – | 7.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 5,255,484 | $44,724,170 | 11.87% |
| TCG Crossover Management, LLC | 3,113,600 | $26,496,736 | 5.16% |
| CAXTON CORP | 156,651 | $1,345,549 | 3.40% |
| VR Adviser, LLC | 1,866,000 | $15,879,660 | 3.10% |
| Novo Holdings A/S | 3,610,461 | $30,725,023 | 2.03% |
| Cormorant Asset Management, LP | 2,536,617 | $21,587 | 1.42% |
| Vivo Capital, LLC | 2,333,300 | $19,856,383 | 1.38% |
| Orbimed Advisors | 5,156,561 | $43,882,334 | 0.86% |
| Frazier Life Sciences Management, L.P. | 1,352,199 | $11,628,911 | 0.84% |
| Bpifrance SA | 2,806,217 | $23,880,907 | 0.61% |